论文部分内容阅读
Objective: Mutations in KRAS oncogene are recognized biomarkers that predict lack of response to anti-epidermal growth factor receptor (EGFR) antibody therapies.However,some patients with KRAS wild-type tumors still do not respond.Therefore, other downstream mutations in BRAE PIK3CA, and NRAS should be investigated.